The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Impairment of dendritic cells (DC), the most effective activators of anticancer immune responses, is one mechanism for defective antitumor immunity, but the causes of DC impairment are incompletely understood. We evaluated the association of impaired DC differentiation with angiogenesis-associated molecules D-dimer, vascular endothelial growth factor (VEGF), urokinase plasminogen activator (uPA), and plasminogen activator inhibitor (PAI-1) in peripheral blood from 41 patients with lung, breast, and colorectal carcinoma. Subsequently, we studied the effect of administration of the anti-VEGF antibody (bevacizumab) on DC maturation and function in vivo. Compared with healthy volunteers, cancer patients had a bias toward the immunoregulatory DC2, had deficits in DC maturation after overnight in vitro culture, and had a significant increase in immature myeloid cell progenitors of DC (0.50 +/- 0.31% vs. 0.32 +/- 0.16% of peripheral blood mononuclear cells, respectively, P = 0.011). A positive correlation was found between the percentage of DC2 and PAI-1 (R = 0.50) and between immature myeloid cells and VEGF (R = 0.52). Bevacizumab administration to cancer patients was associated with a decrease in the accumulation of immature progenitor cells (0.39 +/- 0.30% vs. 0.27 +/- 0.24%, P = 0.012) and induced a modest increase in the DC population in peripheral blood (0.47 +/- 0.23% vs. 0.53 +/- 0.30%). Moreover, anti-VEGF antibody treatment enhanced allo-stimulatory capacity of DC and T cell proliferation against recall antigens. These data suggest that DC differentiation is negatively associated with VEGF levels and may be one explanation for impaired anticancer immunity, especially in patients with advanced malignancies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“improved DC maturation”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Osada et al., 2008
Citations
Cites
Peichev, M., Naiyer, A. J., Pereira, D., Zhu, Z., Lane, W. J., Williams, M., Oz, M. C., Hicklin, D. J., Witte, L., Moore, M. A. S., et al. (2000) · Blood · doi:10.1182/blood.v95.3.952.003k27_952_958 · Cited by 2,277 · cited 1×
“CECs were deWned as CD45¡/Flk+/CD15¡ and CEPs as CD45¡/Flk+/CD133+ [21, 22].”
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977 · cited 3×
“Furthermore, high VEGF levels appear to block DC diVerentiation from immature precursors [16].”
Dhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C., & Bhardwaj, N. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.233 · Cited by 1,359 · cited 1×
“One mechanism for doing so is the inhibition of DC function [ 5 ].”
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337 · cited 2×
“Because Gabrilovich and colleagues [10, 11] showed that the undiVerentiated hematopoietic cells from cancer patients inhibited the function of fully diVerentiated DC, we hypothesized that administration of anti-VEGF Ab”
Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., & Carbone, D. P. (1998) · Blood · doi:10.1182/blood.v92.11.4150 · Cited by 1,048 · cited 1×
“studies performed by Gabrilovich, Carbone, and colleagues [10, 28, 29], the presence of increased iMC in cancer patients, which is associated with elevated levels of VEGF, was demonstrated to be involved in mediating DC dysfunction.”
Regulation of angiogenesis via vascular endothelial growth factor receptors.
Veikkola, T., Karkkainen, M. J., Claesson, L., & Alitalo, K. K. (2000) · PubMed · Cited by 864
SERAFINI, P., BORRELLO, I., & BRONTE, V (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.005 · Cited by 762
Clinical significance of defective dendritic cell differentiation in cancer.
Almand, B., Resser, J. R., Lindman, B. R., Nadaf, S., Clark, J. I., Kwon, E. D., Carbone, D. P., & Gabrilovich, D. I. (2000) · PubMed · Cited by 699
Look, M. P., van Putten, W. L. J., Duffy, M. J., Harbeck, N., Christensen, I. J., Thomssen, C., Kates, R., Spyratos, F., Ferno, M., Eppenberger-Castori, S., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.2.116 · Cited by 596 · cited 1×
“Since PAI-1 is associated with poor prognosis of patients with diVerent types of cancers [24, 25, 30], PAI-1 may have indirect correlation with immunoregulatory DC (DC2).”
The multifaceted circulating endothelial cell in cancer: towards marker and target identification
Bertolini, F., Shaked, Y., Mancuso, P., & Kerbel, R. S. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1971 · Cited by 575 · cited 1×
“CECs were deWned as CD45¡/Flk+/CD15¡ and CEPs as CD45¡/Flk+/CD133+ [21, 22].”
Cited by
Items 201–300 of 324
Mariucci, S., Rovati, B., Manzoni, M., Porta, M. G. D., Comolli, G., Delfanti, S., & Danova, M. (2010) · Clinical and Experimental Medicine · doi:10.1007/s10238-010-0120-7 · Cited by 14
“[102] evaluated the effect of bevacizumab on cancer patients with advanced disease (lung, breast, and colorectal carcinoma).”
Croci, D. O., Méndez‐Huergo, S. P., Cerliani, J. P., & Rabinovich, G. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_29 · Cited by 16
Arai, R. J., Petry, V., Hoff, P. M., & Mano, M. S. (2018) · Biomarker Research · doi:10.1186/s40364-018-0135-x · Cited by 14
“In fact, abrogation of immunobiological responses has been seen in patients treated with anti-VEGF therapy [33].”
BackgroundPromising vaccines for treating glioblastoma
Swartz, A. M., Shen, S. H., Salgado, M. A., Congdon, K. L., & Sanchez-Perez, L. A. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1531846 · Cited by 14
“that it has been shown to be capable of reducing circulating Tregs [102] and enhancing DC stimulatory capacity [103].”
BackgroundNew Strategies for Therapeutic Cancer Vaccines
Qin, H., Sheng, J., Zhang, D., Zhang, X., Liu, L., Li, B., Li, G., & Zhang, Z. (2018) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520618666181109151835 · Cited by 15
Lenvatinib enhances antitumor immunity of anti-PD-1 antibody
Kato, Y. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02721-5 · Cited by 13
“VEGFA and impaired DC population is correlated in cancer patients and anti-VEGFA treatment is associated with decrease in accumulation of immature DC cells [34, 35].”
Yun, J.-A., Kim, J., Baek, Y.-Y., Park, W., Park, M., Kim, S., Kim, T., Choi, S., Jeoung, D., Lee, H., et al. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.117234 · Cited by 14
“In fact, VEGF-A interferes with cell-mediated immunity by decreasing differentiation, recruitment, function of T cells, and development of T cells from early hematopoietic progenitor cells in tumorbearing mice and cancer patients (Ohm et al., 2003; Osada et al., 2008; Shrimali et al., 2010; Terme et al., 2013).”
BackgroundPD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?
Wang, R., Zhang, Y., & Shan, F. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108484 · Cited by 14
Rühle, P. F., Goerig, N. L., Wunderlich, R., Fietkau, R., Gaipl, U. S., Strnad, A. R., & Frey, B. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00296 · Cited by 14
“Besides, the blocking of VEGF might also have a positive effect on dendritic cell (DC) number and maturation (37).”
BackgroundTalla, S. B., Rempel, E., Endris, V., Jenzer, M., Allgäuer, M., Schwab, C., Kazdal, D. N., Stögbauer, F., Volckmar, A., Kocsmár, I., et al. (2020) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22843 · Cited by 14
Tonini, G., Fratto, M. E., Imperatori, M., Pantano, F., Vincenzi, B., & Santini, D. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.63 · Cited by 12
Antiangiogenic therapy in breast cancer
Gampenrieder, S. P., Westphal, T., & Greil, R. (2017) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-017-0362-0 · Cited by 12
Syed, J. S., Brito, J. M., Pooli, A. H., Boutros, P. C., & Shuch, B. M. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.12.003 · Cited by 14
RCC Immune Microenvironment Subsequent to Targeted Therapy: A Friend or a Foe?
Chen, W., Pan, X., & Cui, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.573690 · Cited by 14
“Finally, studies on bevacizumab (65, 66) showed that this VEGF-targeted agent could stimulate the maturation of DCs and decrease Tregs in clinical trials and reduce MDSCs in the tumor site in animal models of RCC (67).”
BackgroundGutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer
Gorgulho, C. M., Krishnamurthy, A., Lanzi, A., Galon, J., Housseau, F., Kaneno, R., & Lotze, M. T. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000357 · Cited by 16
Hickey, M. J., Malone, C. C., Erickson, K. E., Gomez, G. G., Young, E. L., Liau, L. M., Prins, R. M., & Kruse, C. A. (2012) · PubMed · Cited by 12
Zhao, C., Zeng, Y., Kang, N., & Liu, Y. (2024) · Drug Development Research · doi:10.1002/ddr.22257 · Cited by 11
“Finally, dendritic cells, as antigen ‐ presenting cells that activate T ‐ cell immunity, show a negative correlation between their activation level and the concentration of VEGF in the TME (Osada et al., 2008).”
Adhesion to substrates induces dendritic cell endothelization and decreases immunological response
Osterbur, J., Sprague, L., Muccioli, M., Pate, M., Mansfield, K., McGinty, J. W., Li, Y., Li, Y., Shirure, V. S., Courreges, M. C., et al. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.02.003 · Cited by 13
“On the contrary, highlighting the importance of VEGF in this process, cancer patients treated with anti-VEGF antibody showed a decrease in the levels of immunosuppressive DCs (61).”
BackgroundComunanza, V., Gigliotti, C., Lamba, S., Doronzo, G., Vallariello, E., Martin, V., Isella, C., Médico, E., Bardelli, A., Sangiolo, D., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13450 · Cited by 11
Comprehensive Phenotyping of Dendritic Cells in Cancer Patients by Flow Cytometry
Carenza, C., Franzese, S., Calcaterra, F., Mavilio, D., & Bella, S. D. (2020) · Cytometry Part A · doi:10.1002/cyto.a.24245 · Cited by 13
Associating Immunotherapy and Targeted Therapies: Facts and Hopes
Ladoire, S., Rébé, C., & Ghiringhelli, F. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1184 · Cited by 11
Radiothérapie et immunomodulation : mise au point sur les données expérimentales
Deutsch, É., Lévy, A., & Chargari, C. (2015) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2015.05.018 · Cited by 10
Huang, C., Zhang, L., Fang, L., Wen, S., Luo, Y., Liu, H., Liu, J., Zheng, W., Liang, M., Sun, J. L., et al. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.5697 · Cited by 10
“Several methods, including co-culture with marrow stromal cells (42), anti-vascular endothelial growth factor antibody (44) and IL-10 (45), have been used to maintain the immature state of DCs. IL-10-treated DCs induce alloantigen‑specific T cell hyporesponsiveness and are also able to inhibit…”
Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers
Gonzalez, N. S., Castet, F., Élez, E., Macarulla, T. M., & Tabernero, J. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1021772 · Cited by 10
Interface of Signal Transduction Inhibition and Immunotherapy in Melanoma
Shada, A. L., Molhoek, K. R., & Slingluff, C. L. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eb3393 · Cited by 10
Artificial Dendritic Cells: A New Era of Promising Antitumor Immunotherapy
Mateus, D., Sebastião, A. I., Frasco, M. F., Carrascal, M. A., Falcão, A. C., Gomes, C. M. F., Neves, B. M., Sales, M. G. F., & Cruz, M. T. (2023) · Small · doi:10.1002/smll.202303940 · Cited by 9
Zhao, T., Zhang, J., Zhang, Y., Huang, J., Wang, X., Zhang, Y., Zhang, M., Yuan, Y., Xiao, K., Li, H., et al. (2015) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2014.0148 · Cited by 10
“28 31 Thus, selective blocking of VEGFR2 could theoretically reduce unwanted VEGFR1 downstream signals.”
Angiogenic cytokines in renovascular disease: do they have potential for therapeutic use?
Chade, A., & Stewart, N. J. (2013) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2013.01.004 · Cited by 9
Yuan, M., Zhai, Y., & Hui, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.978608 · Cited by 9
“In patients with colorectal cancer, lung cancer, or breast cancer treated with bevacizumab, the number of immature dendritic cells decreased, and the antigenpresenting effect of dendritic cells increased (35).”
BackgroundAnalysis of bevacizumab treatments and metastatic sites of lung cancer
Sato, H., Nagashima, H., Akiyama, M., Ito, T., Hashimoto, T., Saikawa, H., Utsumi, Y., & Maemondo, M. (2020) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2020.100290 · Cited by 9
Kunz, P., Fellenberg, J., Moskovszky, L. E., Sápi, Z., Krenács, T., Poeschl, J., Lehner, B., Szendrői, M., Ewerbeck, V., Kinscherf, R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090727 · Cited by 9
Wang, L., Du, C., Jiang, B., Chen, L., & Wang, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1256740 · Cited by 10
Park, J., Kim, J. C., Lee, M., Lee, J., Kim, Y., Lee, Y. J., Kim, S. W., Kim, S. W., Park, S., & Lee, J. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02455-z · Cited by 8
“However, in these previous studies, bevacizumab was not found to directly regulate Tregs [46, 47].”
Bzowska, M., Mężyk-Kopeć, R., Próchnicki, T., Kulesza, M., Klaus, T., & Bereta, J. (2013) · Acta Biochimica Polonica · doi:10.18388/abp.2013_1982 · Cited by 9
“Therefore, inhibition of the VEGF/VEGFR-1 signaling pathway with bevacizumab could be a strategy to improve dendritic cell maturation and enhance host immune response to tumor (Osada et al., 2008).”
BackgroundD-dimer as an alarming biomarker in various cancers: a review of literature
Vikey, A. K. (2018) · Global Medicine and Therapeutics · doi:10.15761/gmt.1000112 · Cited by 8
Inhibiting VEGF in cancer immunotherapy
Shibata, M., Kono, K., & Takenoshita, S. (2021) · Clinical Immunology Communications · doi:10.1016/j.clicom.2021.12.003 · Cited by 8
Sanches, J. D. S., de Aguiar, R. B., Parise, C. B., Suzuki, J. M., Chammas, R. J., & de Moraes, J. Z. (2016) · Cancer Science · doi:10.1111/cas.12903 · Cited by 8
Advances in Systemic Therapy for Hepatocellular Carcinoma and Future Prospects
Sugimoto, R., Kurokawa, M., Tanaka, Y., Senju, T., Kohjima, M., & Tanaka, M. (2025) · Current Oncology · doi:10.3390/curroncol32090490 · Cited by 8
“…by suppressing immunosuppressive Tregs, restoring the immune activity of CD8+ cells [25], normalizing the tumour vasculature, promoting CD8+ cell infiltration into the tumour [26], and inducing cell death and subsequent cancer antigen release through direct antitumour and necrotic effects [27,28].”
The Current Role of Antiangiogenics in Colorectal Cancer
Basile, D., Nardo, P. D., Daffinà, M. G., Cortese, C., Giuliani, J., & Aprile, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311605 · Cited by 7
Vuong, L. H., Cornish, A. E., Pfeil, J. Q., Khandwala, Y. S., Jiang, H., Zheng, D. X. T., Mascareno, E. A., Rittenhouse, N., Rappold, P. M., Leibold, J., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.05.007 · Cited by 7
Kinase Inhibitors’ Effects on Innate Immunity in Solid Cancers
Peng, C., Rabold, K., Mulder, W. J. M., Jaeger, M., & Netea-Maier, R. T. (2021) · Cancers · doi:10.3390/cancers13225695 · Cited by 7
“First, VEGF has been shown to inhibit DC maturation and antigen presentation, thus hampering T cell activation [62].”
BackgroundLiu, X., Zhou, Q., Xu, Y., Chen, M., Zhao, J., & Wang, M. (2017) · Oncotarget · doi:10.18632/oncotarget.21160 · Cited by 7
“Bevacizumab administration to patients with lung, breast, and colorectal carcinoma was associated with enhancement of DC maturation and antigen presentation [68].”
BackgroundImmune evasion pathways and the design of dendritic cell-based cancer vaccines.
Hanks, B. A. (2016) · PubMed · Cited by 12
A microfluidic competitive immuno-aggregation assay for high sensitivity cell secretome detection
Liu, F., Kc, P., Ni, L., Zhang, G., & Zhe, J. (2018) · Organogenesis · doi:10.1080/15476278.2018.1461306 · Cited by 8
“[9] Osada T, Chong G, Tansik R, Hong T, Spector N,”
BackgroundBorchiellini, D., & Maillet, D. (2022) · Bulletin du Cancer · doi:10.1016/s0007-4551(22)00234-x · Cited by 8
Nakagawa, N., & Kawakami, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.952393 · Cited by 7
Su, J., Zhang, J., Wu, Y., Ni, C., Ding, Y., Cai, Z., Xu, M., Lai, M., Wang, J., Lin, S., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1322473 · Cited by 6
“…the differentiation of monocytes into mature dendritic cells, restricting the differentiation of macrophages into M2 types with immunosuppressive activities, thereby restoring immunosensitive tumor microenvironment (TME) and enhancing the effect of ICIs (Osada et al., 2008; Movahedi et al., 2010).”
BackgroundLi, G., Li, Z., Shen, J., Ma, X., Zheng, S., Zheng, Y., Cao, K., & Dong, N. (2024) · Gene · doi:10.1016/j.gene.2024.148796 · Cited by 7
Cooperative Group Portfolio in Locally Advanced Non–Small-Cell Lung Cancer: Are We Making Progress?
Langer, C. J., Wakelee, H. A., Schiller, J. H., Choy, H., Shepherd, F. A., Vokes, E. E., Adjei, A. A., Baas, P., Saijo, N., & Gandara, D. R. (2008) · Clinical Lung Cancer · doi:10.3816/clc.2008.n.013 · Cited by 6
Arrieta, O. G., Bolaño-Guerra, L. M., Caballé‐Perez, E., Lara‐Mejía, L., Turcott, J. G., Gutiérrez, S., Lozano-Ruiz, F. J., Cabrera-Miranda, L. A., Arroyave-Ramírez, A. M., Maldonado‐Magos, F., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1251620 · Cited by 6
“Additionally, it activates tumor immune response by promoting the maturation and activity of dendritic cells and in fi ltration of T cells (36, 37), minimizing steroid use and facilitating immunotherapy.”
Update on vaccine development for renal cell cancer
Storkus, W. J. (2010) · Research and Reports in Urology · doi:10.2147/oaju.s7242 · Cited by 7
Helfen, A., Schnepel, A., Rieß, J. L., Stölting, M., Gerwing, M., Masthoff, M., Vogl, T., Roth, J., Höltke, C., Wildgruber, M., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9010029 · Cited by 5
“With regard to the changes under Bevacizumab therapy, the hypothesis exists that under physiological conditions VEGF inhibits the maturation of dendritic cells as well as T cells [32,33].”
Guo, H., Miao, L., & Yu, C. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177219 · Cited by 6
Masuda, C., Onishi, S., Yorozu, K., Kurasawa, M., Morinaga, M., Wakita, D., & Sugimoto, M. (2024) · Clinical & Experimental Metastasis · doi:10.1007/s10585-024-10309-y · Cited by 5
“…lymph nodes [36], and some reports suggesting that VEGF could limit the functional maturation of DCs. Clinical data from patients treated with bevacizumab show an increase in the number of mature DCs (maturation markers, CD80, CD83, and CD86) in peripheral blood in response to treatment [37].”
Therapeutic vaccines for non-Hodgkin B-cell lymphoma
Briones, J. (2008) · Clinical & Translational Oncology · doi:10.1007/s12094-008-0249-4 · Cited by 5
“Immunosuppressive molecules secreted by tumours (i.e., VEGF, TGFβ) inhibit DCs and T-cell functioning, and this could be potentially reverted using neutralising monoclonal antibodies against these molecules [ 58 ].”
BackgroundChou, M.-Y., & Yang, M. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102353 · Cited by 6
“…in combination with chemotherapy or radiation, has been associated with increased tumor infiltration by activated effective T cells coupled to Treg and TAM depletion [109], improved DC maturation [110], and downregulation of PD-L1 on malignant and myeloid cells in preclinical cancer models [111].”
A novel function for dendritic cell: Clearance of VEGF via VEGF receptor-1
Xie, Y., Fan, J., Chen, J., Huang, F., Cao, B. B., Tam, P. K. H., & Ren, Y. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.01.043 · Cited by 4
Eralp, Y., & Ateş, U. (2023) · Vaccines · doi:10.3390/vaccines11101545 · Cited by 4
“Earlier observations that have shown an association of bevacizumab use with inhibition of Tregs as well as activation of mature dendritic cell and T cell proliferation lend support to the potential role of anti-angiogenic therapy in generating an immune-friendly TME [68,69].”
BackgroundGenetically Modified Dendritic Cells in Cancer Immunotherapy
Morrison, B. J., Steel, J. C., Gregory, M., Morris, J. C., & Malyguine, A. M. (2009) · Springer eBooks · doi:10.1007/978-0-387-88611-4_23 · Cited by 4
“Moreover, anti-VEGF antibody treatment enhances allostimulatory capacity of DC and T-cell proliferation against recall antigens ( Osada et al. 2008 ).”
BackgroundBevacizumab: Zankapfel der Glioblastomtherapie
Hundsberger, T., & Weller, M. (2017) · Praxis · doi:10.1024/1661-8157/a002650 · Cited by 4
Guan, Z., Han, L., Chen, B., Ma, Y., Ni, Q., Wang, Z., Yang, J., & Liu, Z. (2026) · Oncology Letters · doi:10.3892/ol.2026.15461 · Cited by 3
“VEGF inhibits DC differentiation and maturation through VEGFR binding, reducing antigen presentation and leading to the formation of a ‘cold’ tumor microenvironment (125).”
Perez-Gracia, J. L., Mellado, B., Hansen, A. R., Alonso‐Gordoa, T., Gomez‐Roca, C., Eefsen, R. L., Négrier, S., Suárez, C., Lee, J., Hussain, A., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012466 · Cited by 3
Immunotherapy and Cancer Therapeutics
Chen, G., Jaffee, E. M., & Emens, L. A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00025-7 · Cited by 4
Huemer, F., Gampenrieder, S. P., Schlattau, A., & Greil, R. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.09.009 · Cited by 3
Zheng, K., Fu, S., Zhu, X., Cao, G., Xu, L., Liu, P., Gao, S., Xu, H., Guo, J., Chen, H., et al. (2025) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-24-463 · Cited by 2
“Bevacizumab (a VEGF inhibitors) could facilitate the infiltration of tumors by T-cells and improve the antigen-presenting capacity of circulating dendritic cells, suggesting the stimulation and activation of the immune system when combined with immune checkpoint inhibitors (18,28-31).”
Chen, Z., Zhang, W., Mestanoğlu, M., Cursiefen, C., & Bock, F. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110652 · Cited by 2
Yokota, S., Fujii, W., Motegi, T., Komori, M., Nishi, R., CHAMBERS, J. K., Uchida, K., Yonezawa, T., Momoi, Y., & Maeda, S. (2025) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2025.111019 · Cited by 2
Wang, Y., MaoYan, T., Peng, C., Yang, J., Liu, F., Ding, D., Guo, Y., Yu, Y., & Han, F. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116821 · Cited by 2
A Basic and Clinical Perspective on the Future of Perioperative Therapy for Gastric Cancer
Chen, J., Duda, D. G., Matsui, A., Kikuchi, H., Kawakubo, K., & Kitahara, S. (2019) · Surgery Gastroenterology and Oncology · doi:10.21614/sgo-24-6-273 · Cited by 2
“For example, bevacizumab has shown to enhance dendritic cell (DC) proportion and function in solid cancer patients (34).”
BackgroundGafanov, R. A., Dzidzaria, A. G., Борисович, К. И., & Фастовец, С. В. (2020) · Cancer Urology · doi:10.17650/1726-9776-2020-16-3-29-37 · Cited by 2
“Антиангиогенные препараты могут восстанавливать дифференцировку дендритных клеток, снижать уровень миелоидных клеток-супрессоров и уровни регуляторных Т-клеток [27, 35, 44, 45].”
Kim, K. B. (2012) · Cancer · doi:10.1002/cncr.27756 · Cited by 2
“functions, as demonstrated by bevacizumab enhancing dendritic cell and T lymphocyte proliferation.(10) More selective VEGFR inhibitors have recently”
BackgroundBrem, S. S., & Wong, E. T. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-5316-3.00106-4 · Cited by 2
Ajina, R., Aldeghaither, D. S., Jablonski, S. A., & Weiner, L. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12426-6 · Cited by 3
Genetic analysis of primary renal cell carcinoma to determine treatment approaches
Stühler, V., Rausch, S., Stenzl, A., & Bedke, J. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1874822 · Cited by 2
“immunity, particularly in patients with advanced malignancies [10].”
BackgroundTumor Infiltration by Immune Cells: Pathologic Evaluation and a Clinical Significance
Gutkin, D. W. (2013) · Springer eBooks · doi:10.1007/978-94-007-6217-6_3 · Cited by 2
Lipid peroxidation and superoxide dismutase activity in pea seedlings under clinorotation.
Бараненко, В. В. (1998) · PubMed · Cited by 2
Antiangiogenic drugs as chemosensitizer in melanoma
Quaresmini, D., & Guida, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90190-1.00003-2 · Cited by 1
Goto, Y., Nishio, M., Ohashi, K., Osoegawa, A., Kikuchi, E., Kimura, H., Shimizu, J., Miyauchi, E., Yoshioka, H., Yoshino, I., et al. (2026) · Cancer Science · doi:10.1111/cas.70375 · Cited by 1
Truntzer, C., Thibaudin, M., Bousquet, P. A., Peroz, M., Dérangère, V., Ilie, A., Rageot, D., Flatmark, K., Ree, A. H., Meltzer, S., et al. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2671491 · Cited by 1
“36 37-39 The overall survival benefit observed in the chemoimmunotherapy group in our pooled analysis (HR = 0.58; p = 0.03) is consistent with results from other recent trials evaluating chemoimmunotherapy in MSS mCRC.”
InfluentialImmunotherapy Clinical Trials in Neuro-Oncology
Khagi, S., & Vlahovic, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802420-1.00008-9 · Cited by 1
Dendritic Cells: From Inducers of Specific T-Cell Responses to Promoters of Angiogenesis
Coukos, G., & Benencia, F. (2009) · Springer eBooks · doi:10.1007/978-0-387-88611-4_16 · Cited by 1
“Highlighting the importance of VEGF in this process, patients treated with anti-VEGF antibody showed a decrease in immunosuppressive DC ( Osada et al. 2008 ).”
BackgroundImmunological therapy in urological malignancy: Novel combination strategies
Finley, D. S., Pouliot, F., Chin, A. I., Shuch, B. M., Pantuck, A. J., Belldegrun, A. S., & deKernion, J. B. (2010) · International Journal of Urology · doi:10.1111/j.1442-2042.2010.02664.x · Cited by 1
Combination of Anti-angiogenics and Other Targeted Therapies
Zirlik, K., & Duyster, J. (2019) · Springer eBooks · doi:10.1007/978-3-319-33673-2_14 · Cited by 1
Modulating the Tumor Microenvironment
Ruby, C. E., & Kaufman, H. L. (2011) · Springer eBooks · doi:10.1007/978-1-61779-407-0_18 · Cited by 1
Immunotherapy of renal cell carcinoma: Current state of the problem and promising areas of research
Molchanov, O. (2018) · Urology reports (St - Petersburg) · doi:10.17816/uroved8367-79 · Cited by 2
“В ряде клинических работ установлено снижение эффективности ингибиторов ангиогенеза на фоне высокого уровня плазмоцитоидных и Т-регуляторных клеток [58].”
Combination of Antiangiogenics and Other Targeted Therapies
Zirlik, K., & Duyster, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-31215-6_14-1 · Cited by 1
Tumor microenvironment of colorectal cancer
Gupta, M. K., & Vadde, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24742-2.00024-1 · Cited by 1
Anti-tumor and pro-tumor interactions of human NK cells in cancer
Wong, J. L. (2013) · D-Scholarship@Pitt (University of Pittsburgh)
First-line Treatment of Metastatic Breast Cancer: Focus on Bevacizumab
Fujii, T., Takahashi, H., Matsubayashi, R. N., Inoue, Y., Takenaka, M., Toh, U., Kage, M., Yamana, H., & Shirouzu, K. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s1981
van Cruijsen, H. (2009) · Pure Amsterdam UMC · Cited by 1
Controversies in Neoplastic Myeloplasia
Talmadge, J. E. (2016) · SpringerBriefs in immunology · doi:10.1007/978-3-319-26821-7_1
PD1 and PD-L1 Immune Checkpoint Inhibitors in Gastrointestinal Cancer
Pectasides, E., & McDermott, D. F. (2017) · Springer eBooks · doi:10.1007/978-3-319-43063-8_6 · Cited by 1
General Properties of Dendritic Cell Populations in Cancer
Daniel, B. J., Jeansonne, D. P., Thibodeaux, S. R., & Curiel, T. J. (2009) · Springer eBooks · doi:10.1007/978-0-387-88611-4_5
“Nonetheless, other factors, such as macrophage colony-stimulating factor, IL-6, IL-10, hepatocyte growth factor ( Okunishi et al. 2005 ), transforming growth factor- (Alard et al. 2004), prostaglandin E2 (Pockaj et al. 2004), lactate (Gottfried et al. 2006), or gangliosides (Wolfl et al. 2002) can also inhibit DC diff…”
BackgroundAngiogenic Characteristics of Tumor-Associated Dendritic Cells in Ovarian and Breast Cancer Models
Lewis, D. (2016) · OhioLink ETD Center (Ohio Library and Information Network)
Predictors of Response to Immune Checkpoint Blockade
Andrews, M. C., & Wargo, J. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_31
Interaction between Targeted Therapy and Immunotherapy
Prieto, P. A., Andrews, M. C., Cogdill, A. P., & Wargo, J. A. (2018) · Wiley eBooks · doi:10.1002/9781118684535.ch19
Cancer Vaccines: Dendritic Cell-Based Vaccines and Related Approaches
Chaperot, L., Manches, O., & Aspord, C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99437-6
Translational Biomarkers: Application in the Clinical Development of Combination Therapies
Sukumar, S., & Caculitan, N. G. (2018) · Springer eBooks · doi:10.1007/978-981-13-0496-5_12
Front line of cancer immunotherapy development
Kitano, S. (2017) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.106.2645 · Cited by 1
Metadata
- Authors
- Osada, T., Chong, G., Tansik, R., Hong, T., Spector, N., Kumar, R., Hurwitz, H. I., Dev, I., Nixon, A. B., Lyerly, H. K., Clay, T., & Morse, M. A.
- Affiliations
- Duke Medical Center (US)
- GlaxoSmithKline (United Kingdom) (GB)
- Hartford Hospital (US)
- Corresponding author
- Morse, Michael A.
- ORCID
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2008-01-10
- Volume
- 57
- Issue
- 8
- Pages
- 1115-1124
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC4110970
- OpenAlex
- W2067969350
- Cited by
- 311
- References
- 35
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 15 · 2023: 22 · 2022: 18 · 2021: 30 · 2020: 26 · 2019: 16 · 2018: 24 · 2017: 21 · 2016: 19 · 2015: 12 · 2014: 13 · 2013: 14 · 2012: 10
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- GlaxoSmithKline
- National Cancer Institute (K24CA113755, P01CA078673, 5 P01 CA78673.)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- anti-VEGF therapy, bevacizumab, dendritic cells, immature myeloid cells, DC2, dendritic cell maturation, vascular endothelial growth factor, angiogenesis, plasminogen activator inhibitor-1, urokinase, D-dimer, antitumor immunity, lung cancer, breast cancer, colorectal cancer, T cell proliferation
- MeSH terms
- Bevacizumab, Antibodies, Monoclonal, Breast Neoplasms, Cell Differentiation, Cells, Cultured, Dendritic Cells, Fibrin Fibrinogen Degradation Products, Humans, Immunotherapy, Lung Neoplasms, Neovascularization, Pathologic, Pilot Projects, T-Lymphocytes, Urokinase-Type Plasminogen Activator, Colorectal Neoplasms, Plasminogen Activator Inhibitor 1, Angiogenesis Inhibitors, Myeloid Progenitor Cells, Vascular Endothelial Growth Factor A, Cell Proliferation, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.